

Figure 1: Standard curve for BVDV




Figure 2: Growth dynamics of BVDV in MDBK cells




Figure 3: Anti-BVDV compound screening (40 µM) in MDBK cells

NO = no treatment;

RIB = Ribavirin;

A = 1-(2-chloro-2-deoxy-β-D-ribofuranosyl)-4-amino-1H-pyrimidin-2-one;

B = 1-(β-D-ribo-furanosyl)-5-nitro-1H,3H-pyrimidin-2,4-dione;

C = 1-(β-D-ribo-furanosyl)-4-amino-5-methyl-1H-pyrimidin-2-one;

D = 1-(α-L-manno-furanosyl)-4-benzamido-1H-pyrimidin-2-one;

E = 1-(β-D-ribo-furanosyl)-6-methyl-1H,3H-pyrimidin-2,4-dione;

F = 1-(2,3-di-O-methyl-β-D-ribofuranosyl)-4-butylamino-1H-pyrimidin-2-one;

G = S1, S2-bis [1-(β-D-ribo-furanosyl)-1H-pyrimidin-2-one]-4,4-disulfide;

H = 1-(β-D-ribo-furanosyl)-2-methoxy-1H-pyrimidin-4-one;

I = 5-hydroxyuridine (β-D-CL, R = X = OH);

J = 1-(β-D-ribo-furanosyl)-5-bromo-1H,3H-pyrimidin-2,4-dione;

K = 1-(β-D-ribo-furanosyl)-2-amino-1H-pyrimidin-2-one;

L = 1-(β-D-ribo-furanosyl)-1H,3H-pyrimidin-2,4-dithione;

M = 1-(5-deoxy-β-D-ribofuranosyl)-1H,3H-pyrimidin-2,4-dione;

N = 1-(β-D-ribo-furanosyl)-2,5-diamino-1H-pyrimidin-2-one;

O = 1-(β-D-ribo-furanosyl)-6-hydroxy-1H,3H-pyrimidin-2,4-dione;

P = 5-bromouridine;

Q = 1-(β-D-ribo-furanosyl)-5-benzyloxy-6-allyl-1H,3H-pyrimidin-2,4-dione;

R = 1-(β-D-ribo-furanosyl)-5-hydroxy-6-propyl-1H,3H-pyrimidin-2,4-dione;

S = 5-O-(1-p-nitrophenyltetrazol-5-yl)-6-propyl-uridine.







Figure 4: Prevention of β -D-GA toxicity in SUDH1-1 cells




ribavirin




β -D-AJ




β -D-BS



β -D-CL



β -D-DJ



β -D-GA

Figure 5